Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients

BMC Nephrology

Jonathan Himmelfarb¹  Rajnish Mehrotra¹  Charles D. Ellis²  T. Alp Ikizler²  Matthew B. Rivara¹ 

[1] Kidney Research Institute, Seattle, WA, USA;Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, TN, USA

关键词: IL-6;    CRP;    Isofurans;    F2-isoprostanes;    Oxidative stress;    Hemodialysis;    End stage renal disease;    Erythropoietin;    Chronic inflammation;   

Others  :  1220065
DOI  :  10.1186/s12882-015-0074-9

 received in 2014-11-12, accepted in 2015-05-21,  发布年份 2015

【 摘 要 】

Background

In patients undergoing maintenance hemodialysis (HD), hyporesponsiveness to erythropoiesis stimulating agents (ESAs) is associated with adverse clinical outcomes. Systemic inflammation is highly prevalent in HD patients and is associated with ESA hyporesponsiveness. Oxidative stress is also highly prevalent in HD patients, but no previous study has determined its association with ESA response. This study assessed the association of plasma markers of oxidative stress and inflammation with ESA resistance in patients undergoing maintenance HD.

Methods

We analyzed data from 165 patients enrolled in the Provision of Antioxidant Therapy in Hemodialysis study, a randomized controlled trial evaluating antioxidant therapy in prevalent HD patients. Linear and mixed-effects regression were used to assess the association of baseline and time-averaged high sensitivity F2-isoprostanes, isofurans, C-reactive protein (hsCRP), and interleukin-6 (IL-6) with ESA resistance index (ERI), defined as the weekly weight-adjusted ESA dose divided by blood hemoglobin level. Unadjusted models as well as models adjusted for potential confounders were examined. Predicted changes in ERI per month over study follow-up among baseline biomarker quartiles were also assessed.

Results

Patients with time-averaged isofurans in the highest quartile had higher adjusted mean ERI compared with patients in the lowest quartile (β = 14.9 ng/ml; 95 % CI 7.70, 22.2; reference group <0.26 ng/ml). The highest quartiles of hsCRP and IL-6 were also associated with higher adjusted mean ERI (β = 10.8 mg/l; 95 % CI 3.52, 18.1 for hsCRP; β = 10.2 pg/ml; 95 % CI 2.98, 17.5 for IL-6). No significant association of F2-isoprostanes concentrations with ERI was observed. Analyses restricted to baseline exposures and ERI showed similar results. Baseline hsCRP, IL-6, and isofurans concentrations in the highest quartiles were associated with greater predicted change in ERI over study follow-up compared to the lowest quartiles (P = 0.008, P = 0.004, and P = 0.04, respectively). There was no association between baseline F2-isoprostanes quartile and change in ERI.

Conclusions

In conclusion, higher concentrations of isofurans, hsCRP and IL-6, but not F2-isoprostanes, were associated with greater resistance to ESAs in prevalent HD patients. Further research is needed to test whether interventions that successfully decrease oxidative stress and inflammation in patients undergoing maintenance HD improve ESA responsiveness.

【 授权许可】

   
2015 Rivara et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2013.
• [2]Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010; 303:857-64.
• [3]Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2011; 6:1973-81.
• [4]Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J et al.. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17:1181-91.
• [5]Duong U, Kalantar-Zadeh K, Molnar MZ, Zaritsky JJ, Teitelbaum I, Kovesdy CP et al.. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol. 2012; 35:198-208.
• [6]Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S et al.. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011; 26:2641-8.
• [7]Solomon SD, Uno H, Lewis EF, Eckardt K-U, Lin J, Burdmann EA et al.. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010; 363:1146-55.
• [8]Charytan C. Bundled-rate legislation for medicare reimbursement for dialysis services: implications for anemia management with ESAs. Clin J Am Soc Nephrol. 2010; 5:2355-62.
• [9]Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L et al.. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55:1899-911.
• [10]Kaysen GA, Dubin JA, Müller H-G, Mitch WE, Rosales LM, Levin NW. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 2002; 61:2240-9.
• [11]Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC et al.. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013; 28:1936-45.
• [12]Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrol. 2013; 14:67. BioMed Central Full Text
• [13]Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33:63-72.
• [14]Sirken G, Kung S-C, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J Am Soc Artif Intern Organs. 2003; 49:422-5.
• [15]Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004; 15:1877-82.
• [16]Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62:1524-38.
• [17]Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM et al.. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002; 58:190-7.
• [18]Alkazemi D, Egeland GM, Roberts LJ, Kubow S. Isoprostanes and isofurans as non-traditional risk factors for cardiovascular disease among Canadian Inuit. Free Radic Res. 2012; 46:1258-66.
• [19]Ware LB, Fessel JP, May AK, Roberts LJ. Plasma biomarkers of oxidant stress and development of organ failure in severe sepsis. Shock Augusta Ga. 2011; 36:12-7.
• [20]Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P et al.. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin Nephrol. 1999; 52:239-45.
• [21]Suliman HB, Ali M, Piantadosi CA. Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia. Blood. 2004; 104:43-50.
• [22]Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin Dial. 2004; 17:449-54.
• [23]Himmelfarb J, Ikizler TA, Ellis C, Wu P, Shintani A, Dalal S et al.. Provision of Antioxidant Therapy in Hemodialysis (PATH): A Randomized Clinical Trial. J Am Soc Nephrol. 2013; 25:623-33.
• [24]Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2- isoprostanes and isofurans using gas chromatography–mass spectrometry. Free Radic Biol Med. 2013; 59:36-44.
• [25]Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int. 2011; 80:464-74.
• [26]Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro‐inflammatory cytokines. Nephrol Dial Transplant. 2002; 17(suppl 11):39-43.
• [27]Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK et al.. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113:1271-6.
• [28]Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998; 18:555-9.
• [29]Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med. 1999; 47:204-11.
• [30]Dallalio G, Law E, Robert T, Means J. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood. 2006; 107:2702-4.
• [31]Deliconstantinos G, Villiotou V, Stavrides JC, Salemes N, Gogas J. Nitric oxide and peroxynitrite production by human erythrocytes: a causative factor of toxic anemia in breast cancer patients. Anticancer Res. 1995; 15:1435-46.
• [32]Kato A, Odamaki M, Hishida A. Blood 8‐hydroxy‐2′‐deoxyguanosine is associated with erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant. 2003; 18:931-6.
• [33]Lang F, Qadri SM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif. 2012; 33:125-30.
• [34]Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Föller M et al.. Suicidal erythrocyte death in end-stage renal disease. J Mol Med. 2014; 92:871-9.
• [35]Kalim S, Tamez H, Wenger J, Ankers E, Trottier CA, Deferio JJ et al.. Carbamylation of Serum Albumin and Erythropoietin Resistance in End Stage Kidney Disease. Clin J Am Soc Nephrol. 2013; 8:1927-34.
• [36]Platel A, Nesslany F, Gervais V, Marzin D. Study of oxidative DNA damage in TK6 human lymphoblastoid cells by use of the in vitro micronucleus test: determination of no-observed-effect levels. Mutat Res. 2009; 678:30-7.
• [37]Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004; 43:1731-7.
• [38]Fessel JP, Jackson Roberts L. Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension. Antioxid Redox Signal. 2004; 7:202-9.
• [39]Rowley S, Liang L-P, Fulton R, Shimizu T, Day B, Patel M. Mitochondrial respiration deficits driven by reactive oxygen species in experimental temporal lobe epilepsy. Neurobiol Dis. 2015; 75:151-8.
• [40]Victor VM, Rovira-Llopis S, Saiz-Alarcon V, Sangüesa MC, Rojo-Bofill L, Bañuls C et al.. Altered mitochondrial function and oxidative stress in leukocytes of anorexia nervosa patients. PLoS ONE. 2014; 9: Article ID e106463
• [41]Mille-Hamard L, Billat VL, Henry E, Bonnamy B, Joly F, Benech P et al.. Skeletal muscle alterations and exercise performance decrease in erythropoietin-deficient mice: a comparative study. BMC Med Genomics. 2012; 5:29. BioMed Central Full Text
• [42]Stoyanoff TR, Todaro JS, Aguirre MV, Zimmermann MC, Brandan NC. Amelioration of lipopolysaccharide-induced acute kidney injury by erythropoietin: involvement of mitochondria-regulated apoptosis. Toxicology. 2014; 318:13-21.
• [43]Wu C-L, Chen S-D, Yin J-H, Hwang C-S, Yang D-I. Erythropoietin and sonic hedgehog mediate the neuroprotective effects of brain-derived neurotrophic factor against mitochondrial inhibition. Neurobiol Dis. 2010; 40:146-54.
• [44]Bamgbola OF, Kaskel FJ, Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol. 2009; 24:571-9.
• [45]Locatelli F, Andrulli S, Memoli B, Maffei C, Vecchio LD, Aterini S et al.. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006; 21:991-8.
• [46]Vega A, Ruiz C, Abad S, Quiroga B, Velázquez K, Yuste C et al.. Body composition affects the response to erythropoiesis-stimulating agents in patients with chronic kidney disease in dialysis. Ren Fail. 2014; 36:1073-7.